Vaso (VASO) AI Stock Analysis

• Market Cap: $21.77M
• Dividend Yield: N/A
• Average Volume (3M): 53.87K
• Price to Earnings (P/E): 21.0
• Beta (1Y): 0.05
• Revenue Growth: 8.63%
• EPS Growth: -67.03%
• Country: US
• Employees: 298
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 175,741,320
• 10 Day Avg. Volume: 89,017
• 30 Day Avg. Volume: 53,869
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.13
• Enterprise Value/Revenue: -0.03
• Enterprise Value/Gross Profit: -0.05
• Enterprise Value/Ebitda: -1.52
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Vaso's strong financial performance is the primary driver of its overall score, supported by robust cash flow and a solid balance sheet. However, the weak technical indicators and moderate valuation, combined with low profitability metrics, temper the overall score. The lack of earnings call insights and significant corporate events further limits the potential for a higher score.

Vaso Business Overview & Revenue Model

Company Description

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

How the Company Makes Money

Vaso Corporation generates revenue through the sale and leasing of its medical devices, particularly the EECP Therapy systems. These systems are sold to hospitals, clinics, and other healthcare providers both domestically and internationally. In addition to device sales, Vaso Corporation earns income from its managed network and IT services division, which provides comprehensive solutions to the healthcare industry, including network design, implementation, and support services. Key revenue streams include product sales, service contracts, and leasing arrangements. The company also benefits from partnerships with healthcare organizations and institutions that enhance its reach and service offerings.

Vaso Financial Statement Overview

Summary

Vaso demonstrates a strong financial position with steady revenue growth and a robust balance sheet characterized by low leverage. Profitability metrics indicate room for improvement, but the company's cash flow performance is commendable, highlighting its ability to generate cash efficiently.

Income Statement

Vaso shows a solid performance with steady revenue growth, achieving a 7.98% increase from 2023 to the TTM. The gross profit margin is healthy at 59.98% for TTM, indicating efficient cost management. However, the net profit margin is relatively low at 1.20% in TTM, and EBIT margin is only 0.74%, suggesting room for profitability improvement. EBITDA margin at 2.13% for TTM also points to moderate operational efficiency.

Balance Sheet

Vaso's balance sheet is strong, with a low debt-to-equity ratio of 0.08 in TTM, indicating minimal leverage and financial risk. The equity ratio of 34.20% shows a stable financial structure. The ROE is modest at 3.94% in TTM, reflecting moderate returns on investments made by shareholders.

Cash Flow

Vaso's cash flow is robust, with free cash flow showing significant growth of 120.76% from 2023 to TTM. The operating cash flow to net income ratio is favorable at 3.61 for TTM, suggesting efficient cash generation relative to net income. The free cash flow to net income ratio is also strong at 3.85, indicating good cash conversion efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	86.77M	81.02M	80.02M	75.58M	69.85M
Gross Profit	52.05M	50.59M	48.48M	43.13M	38.57M
EBITDA	2.10M	5.95M	8.38M	6.66M	3.23M
Net Income	951.00K	4.80M	11.87M	6.10M	358.00K
Balance Sheet
Total Assets	82.94M	75.76M	72.66M	52.36M	50.38M
Cash, Cash Equivalents and Short-Term Investments	26.27M	25.32M	20.32M	6.65M	7.58M
Total Debt	2.38M	2.06M	1.81M	1.39M	13.19M
Total Liabilities	55.24M	48.91M	49.78M	41.05M	45.29M
Stockholders Equity	27.70M	26.84M	22.88M	11.31M	5.08M
Cash Flow
Free Cash Flow	1.83M	4.57M	13.85M	7.40M	4.93M
Operating Cash Flow	3.28M	5.30M	14.42M	7.82M	5.93M
Investing Cash Flow	11.73M	-5.66M	-8.42M	-260.00K	-575.00K
Financing Cash Flow	-89.00K	-134.00K	-230.00K	-8.33M	-553.00K

Vaso Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VASO, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.13, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 60.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VASO.

Vaso Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥342.43B	8.69	-3.93%	2.47%	11.18%	-19.47%
VASO	64 Neutral	$21.77M	21.02	4.02%	―	8.63%	-67.03%
MSPR	47 Neutral	$8.09M	―	-458.99%	―	34.74%	-53.67%
VSEE	46 Neutral	$20.99M	―	-3190.66%	―	―	-806.84%
ZCMD	43 Neutral	$24.77M	―	-3.31%	―	-18.37%	71.61%
BFRG	―	$12.62M	―	-141.43%	―	―	―
MGRX	―	$18.84M	―	-115.87%	―	―	―

Vaso Corporate Events

Vaso Announces Major Management Changes for 2025

Vaso announced significant management changes effective January 1, 2025. Jane Moen has been appointed as the Chief Operating Officer, while Peter C. Castle will remain as President of VasoTechnology, Inc. Michael Beecher steps down as Co-Chief Financial Officer and Secretary, with Jonathan Newton assuming the role of Chief Financial Officer, Treasurer, and Secretary.